

Co-Diagnostics, DNA Logix JV to target poor nations

24 July 2013 | News | By BioSpectrum Bureau



Singapore: US-based Co-Diagnostics and DNA Logix have formed a joint venture, Co-Diagnostics HBDC to address diagnostic problems for infectious diseases unique to high burden developing countries (HBDC).

It is estimated that while HBDC's have 90 percent of the burden of disease worldwide, only about 10 percent of R&D is devoted to them. Co-Diagnostics HBDC will sell testing products and services to these middle and low-income countries based on proprietary real-time PCR testing technology developed by DNA Logix and licensed to Co-Diagnostics HBDC specifically for that market.

Co-Diagnostics is a leading DNA testing company and recently acquired the suite of DNA testing technologies from DNA Logix to be used in their joint venture. DNA Logix is the first company to use mathematics to create entirely new forms of diagnostic tests, often with multiple-order-of-magnitude improvements in performance.

"The business models that are currently used for diagnostic testing in the US are not the most effective business models in other countries. We are excited to create an entity with the tools and focus necessary to solve problems internationally," said Mr Dwight Egan, president, Co-Diagnostics.

Dr Brent C Satterfield, CEO, DNA Logix, added that, "There is a lot of unmet need in the world. We are glad that Co-Diagnostics is engaged in this effort, and we believe that innovative testing technologies, combined with forward-thinking business models, will allow us to reach a much larger number of people."